DLA Piper advised Cantor Fitzgerald, the dealer manager in connection with an offer to exchange certain outstanding warrants to purchase Class A ordinary shares of Zura Bio Limited, and the related solicitation of consents to certain amendments to the warrant agreement governing such warrants.
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases.
The DLA Piper team was led by partner Stephen Alicanti (New York) and included partners Christopher Mikson and Bill Bartow (both in Philadelphia), Kurtis Weaver (Boston), Brad Rock (San Francisco) and associates Jenna Fontenot (Miami) and Priya Narahari (Philadelphia).
DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.
